دورية أكاديمية
Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment.
العنوان: | Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment. |
---|---|
المؤلفون: | Méndez-Álvarez D; Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico., Torres-Rojas MF; Laboratorio de Biomedicina Molecular 2, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Ciudad de México 07320, Mexico., Lara-Ramirez EE; Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico., Marchat LA; Laboratorio de Biomedicina Molecular 2, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Ciudad de México 07320, Mexico., Rivera G; Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. |
المصدر: | Molecules (Basel, Switzerland) [Molecules] 2023 May 27; Vol. 28 (11). Date of Electronic Publication: 2023 May 27. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, c1995- |
مواضيع طبية MeSH: | Molecular Dynamics Simulation* , Receptors, Estrogen*, Molecular Docking Simulation ; Ligands ; Estrogen Receptor beta |
مستخلص: | Obesity is a pandemic and a serious health problem in developed and undeveloped countries. Activation of estrogen receptor beta (ERβ) has been shown to promote weight loss without modifying caloric intake, making it an attractive target for developing new drugs against obesity. This work aimed to predict new small molecules as potential ERβ activators. A ligand-based virtual screening of the ZINC15, PubChem, and Molport databases by substructure and similarity was carried out using the three-dimensional organization of known ligands as a reference. A molecular docking screening of FDA-approved drugs was also conducted as a repositioning strategy. Finally, selected compounds were evaluated by molecular dynamic simulations. Compounds 1 (-24.27 ± 0.34 kcal/mol), 2 (-23.33 ± 0.3 kcal/mol), and 6 (-29.55 ± 0.51 kcal/mol) showed the best stability on the active site in complex with ERβ with an RMSD < 3.3 Å. RMSF analysis showed that these compounds do not affect the fluctuation of the Cα of ERβ nor the compactness according to the radius of gyration. Finally, an in silico evaluation of ADMET showed they are safe molecules. These results suggest that new ERβ ligands could be promising molecules for obesity control. |
References: | Eur J Clin Invest. 2012 Dec;42(12):1287-94. (PMID: 23033884) Climacteric. 2005 Aug;8 Suppl 1:3-63. (PMID: 16112947) Mol Cell Endocrinol. 2019 Jan 5;479:147-158. (PMID: 30342056) J Diabetes Investig. 2015 May;6(3):325-33. (PMID: 25969718) J Enzyme Inhib Med Chem. 2017 Dec;32(1):444-451. (PMID: 28097916) Nat Rev Drug Discov. 2022 Mar;21(3):201-223. (PMID: 34815532) N Engl J Med. 2017 Jul 6;377(1):13-27. (PMID: 28604169) Int J Mol Sci. 2019 Nov 20;20(23):. (PMID: 31757043) BMC Res Notes. 2012 Jul 23;5:367. (PMID: 22824207) Mol Biol (Mosk). 2008 Jul-Aug;42(4):701-6. (PMID: 18856071) Reprod Med Biol. 2016 Dec 05;16(1):4-20. (PMID: 29259445) J Cheminform. 2011 Oct 07;3:33. (PMID: 21982300) J Cheminform. 2015 Jun 22;7:26. (PMID: 26101548) Pflugers Arch. 2020 May;472(5):583-596. (PMID: 32358780) Front Endocrinol (Lausanne). 2017 Oct 19;8:281. (PMID: 29097993) Pharmacol Rev. 2018 Oct;70(4):712-746. (PMID: 30087160) Ther Adv Endocrinol Metab. 2020 Jan 22;11:2042018819897527. (PMID: 32030121) J Biol Chem. 2010 Oct 8;285(41):31292-303. (PMID: 20657011) Sci Rep. 2017 Jul 5;7(1):4663. (PMID: 28680060) J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254) PLoS One. 2020 Jan 14;15(1):e0227490. (PMID: 31935249) Adv Protein Chem Struct Biol. 2016;102:181-224. (PMID: 26827606) Nat Protoc. 2016 May;11(5):905-19. (PMID: 27077332) ACS Med Chem Lett. 2023 Mar 09;14(4):479-486. (PMID: 37077391) Steroids. 2014 Nov;90:13-29. (PMID: 24971815) Data Brief. 2021 Mar 15;35:106948. (PMID: 33855133) Nucleic Acids Res. 2021 Jul 2;49(W1):W5-W14. (PMID: 33893803) Molecules. 2018 Apr 28;23(5):. (PMID: 29710787) Nucleic Acids Res. 2021 Jul 2;49(W1):W530-W534. (PMID: 33950214) J Chem Inf Model. 2014 Jul 28;54(7):1951-62. (PMID: 24850022) Am J Clin Nutr. 2005 May;81(5):1072-9. (PMID: 15883431) FASEB J. 2017 Jan;31(1):266-281. (PMID: 27733447) Cell Metab. 2011 Sep 7;14(3):289-99. (PMID: 21907136) Biomedicines. 2020 Nov 18;8(11):. (PMID: 33217950) Metabolism. 2019 Mar;92:170-192. (PMID: 30391259) Antimicrob Agents Chemother. 2006 Mar;50(3):1045-53. (PMID: 16495267) |
فهرسة مساهمة: | Keywords: estrogen receptor beta; ligand-based virtual screening; molecular docking; molecular dynamics; obesity |
المشرفين على المادة: | 0 (Receptors, Estrogen) 0 (Ligands) 0 (Estrogen Receptor beta) |
تواريخ الأحداث: | Date Created: 20230610 Date Completed: 20230612 Latest Revision: 20230612 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC10254148 |
DOI: | 10.3390/molecules28114389 |
PMID: | 37298864 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1420-3049 |
---|---|
DOI: | 10.3390/molecules28114389 |